Compare Stocks: ICCC, PALI, IKT, and VNDA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ICCC ImmuCell	$9.79 -0.6%	$10.55	$4.52 ▼ $12.10	$88.89M	0.54	24,618 shs	8,476 shs
IKT Inhibikase Therapeutics	$2.37 +1.1%	$2.31	$1.33 ▼ $2.61	$330.01M	0.95	1.15 million shs	187,611 shs
PALI Palisade Bio	$2.08 +0.7%	$2.03	$0.55 ▼ $2.86	$361.61M	1.53	3.56 million shs	1.01 million shs
VNDA Vanda Pharmaceuticals	$5.15 +1.1%	$5.42	$4.27 ▼ $9.94	$311.07M	0.64	1.56 million shs	234,721 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ICCC ImmuCell	0.00%	-0.51%	-1.99%	+3.36%	+66.39%
IKT Inhibikase Therapeutics	0.00%	-6.40%	-2.90%	+40.12%	+50.00%
PALI Palisade Bio	0.00%	-1.44%	-3.74%	+21.89%	+244.48%
VNDA Vanda Pharmaceuticals	0.00%	-6.26%	-2.49%	-13.44%	+12.86%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ICCC ImmuCell	$9.79 -0.6%	$10.55	$4.52 ▼ $12.10	$88.89M	0.54	24,618 shs	8,476 shs
IKT Inhibikase Therapeutics	$2.37 +1.1%	$2.31	$1.33 ▼ $2.61	$330.01M	0.95	1.15 million shs	187,611 shs
PALI Palisade Bio	$2.08 +0.7%	$2.03	$0.55 ▼ $2.86	$361.61M	1.53	3.56 million shs	1.01 million shs
VNDA Vanda Pharmaceuticals	$5.15 +1.1%	$5.42	$4.27 ▼ $9.94	$311.07M	0.64	1.56 million shs	234,721 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ICCC ImmuCell	0.00%	-0.51%	-1.99%	+3.36%	+66.39%
IKT Inhibikase Therapeutics	0.00%	-6.40%	-2.90%	+40.12%	+50.00%
PALI Palisade Bio	0.00%	-1.44%	-3.74%	+21.89%	+244.48%
VNDA Vanda Pharmaceuticals	0.00%	-6.26%	-2.49%	-13.44%	+12.86%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ICCC ImmuCell	2.00	Hold	N/A	N/A
IKT Inhibikase Therapeutics	3.00	Buy	$5.40	128.33% Upside
PALI Palisade Bio	3.00	Buy	$9.00	333.73% Upside
VNDA Vanda Pharmaceuticals	2.50	Moderate Buy	$13.70	166.28% Upside

Current Analyst Ratings Breakdown

Latest ICCC, PALI, IKT, and VNDA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2026	ICCC ImmuCell	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Hold (C-)
8/10/2026	VNDA Vanda Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$21.00 ➝ $20.00
8/10/2026	VNDA Vanda Pharmaceuticals	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$17.00 ➝ $12.00
7/31/2026	IKT Inhibikase Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00
7/23/2026	PALI Palisade Bio	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$8.00
7/17/2026	IKT Inhibikase Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	VNDA Vanda Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/14/2026	PALI Palisade Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/13/2026	IKT Inhibikase Therapeutics	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/2/2026	ICCC ImmuCell	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/30/2026	PALI Palisade Bio	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$7.00

(Data available from 9/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ICCC ImmuCell	$27.64M	3.22	$0.19 per share	51.09	$2.99 per share	3.27
IKT Inhibikase Therapeutics	$260K	1,269.28	N/A	N/A	$2.30 per share	1.03
PALI Palisade Bio	$250K	1,446.44	N/A	N/A	$0.87 per share	2.39
VNDA Vanda Pharmaceuticals	$216.10M	1.44	N/A	N/A	$5.54 per share	0.93

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ICCC ImmuCell	-$1.04M	$0.08	122.39	N/A	N/A	2.57%	2.69%	1.76%	11/12/2026 (Estimated)
IKT Inhibikase Therapeutics	-$48.26M	-$0.43	N/A	N/A	N/A	N/A	-42.80%	-40.58%	N/A
PALI Palisade Bio	-$16.78M	-$0.48	N/A	N/A	N/A	N/A	-33.47%	-31.79%	11/9/2026 (Estimated)
VNDA Vanda Pharmaceuticals	-$220.47M	-$4.63	N/A	N/A	N/A	-127.41%	-49.81%	-33.29%	11/4/2026 (Estimated)

Latest ICCC, PALI, IKT, and VNDA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	ICCC ImmuCell	$0.05	$0.20	+$0.15	$0.20	$5.40 million	$7.19 million
8/11/2026	Q2 2026	IKT Inhibikase Therapeutics	-$0.09	-$0.11	-$0.02	-$0.11	N/A	N/A
8/10/2026	Q2 2026	PALI Palisade Bio	-$0.0522	-$0.05	+$0.0022	-$0.05	$0.50 million	$0.50 million
8/5/2026	Q2 2026	VNDA Vanda Pharmaceuticals	-$0.5825	-$1.04	-$0.4575	-$1.04	$61.93 million	$50.53 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ICCC ImmuCell	N/A	N/A	N/A	N/A	N/A
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	N/A
PALI Palisade Bio	N/A	N/A	N/A	N/A	N/A
VNDA Vanda Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ICCC ImmuCell	0.22	4.75	2.71
IKT Inhibikase Therapeutics	N/A	15.82	15.82
PALI Palisade Bio	N/A	24.26	24.26
VNDA Vanda Pharmaceuticals	0.01	1.61	1.60

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ICCC ImmuCell	13.47%
IKT Inhibikase Therapeutics	3.81%
PALI Palisade Bio	11.79%
VNDA Vanda Pharmaceuticals	88.14%

Insider Ownership

Company	Insider Ownership
ICCC ImmuCell	5.70%
IKT Inhibikase Therapeutics	7.10%
PALI Palisade Bio	0.07%
VNDA Vanda Pharmaceuticals	10.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ICCC ImmuCell	70	9.08 million	8.56 million	Not Optionable
IKT Inhibikase Therapeutics	6	139.54 million	129.63 million	N/A
PALI Palisade Bio	14	174.27 million	174.15 million	Not Optionable
VNDA Vanda Pharmaceuticals	290	60.46 million	53.99 million	Optionable

ICCC, PALI, IKT, and VNDA Headlines

Recent News About These Companies

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Receives Consensus Rating of "Moderate Buy" from Brokerages

September 7, 2026 | marketbeat.com

Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences

September 2, 2026 | prnewswire.com

BlackRock Inc. Makes New Investment in Vanda Pharmaceuticals Inc. $VNDA

September 1, 2026 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Invests $1.32 Million in Vanda Pharmaceuticals Inc. $VNDA

August 31, 2026 | marketbeat.com

Ieq Capital LLC Makes New Investment in Vanda Pharmaceuticals Inc. $VNDA

August 26, 2026 | marketbeat.com

Vanda Pharmaceuticals Inc. (VNDA)

August 25, 2026 | finance.yahoo.com

Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission

August 24, 2026 | prnewswire.com

NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.

August 22, 2026 | prnewswire.com

Monaco Asset Management SAM Invests $1.35 Million in Vanda Pharmaceuticals Inc. $VNDA

August 17, 2026 | marketbeat.com

AIGH Capital Management LLC Purchases New Stake in Vanda Pharmaceuticals Inc. $VNDA

August 17, 2026 | marketbeat.com

Vanda (VNDA) Q2 2026 Earnings Call Transcript

August 12, 2026 | finance.yahoo.com

4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026

August 11, 2026 | zacks.com

Vanda Pharmaceuticals Inc. (VNDA) Q2 2026 Earnings Call Transcript

August 6, 2026 | seekingalpha.com

Vanda Pharmaceuticals Balances Strong Growth With Rising Losses

August 5, 2026 | tipranks.com

Vanda: Q2 Earnings Snapshot

August 5, 2026 | chron.com

Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Lags Revenue Estimates

August 5, 2026 | zacks.com

Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results

August 5, 2026 | prnewswire.com

Vanda Pharmaceuticals Inc. (VNDA) Stock Price, News, Quote & History - Yahoo Finance

July 29, 2026 | finance.yahoo.com

Vanda Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 5, 2026

July 29, 2026 | prnewswire.com

Vanda Pharmaceuticals: Risks Rising, Rewards Dwindling - Why I'm Downgrading To Hold

July 17, 2026 | seekingalpha.com

Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a ...

July 17, 2026 | uk.finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ICCC, PALI, IKT, and VNDA Company Descriptions

ImmuCell NASDAQ:ICCC

$9.79 -0.06 (-0.61%)

As of 02:06 PM Eastern

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

Inhibikase Therapeutics NASDAQ:IKT

$2.37 +0.03 (+1.07%)

As of 02:11 PM Eastern

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.

Palisade Bio NASDAQ:PALI

$2.08 +0.02 (+0.73%)

As of 02:12 PM Eastern

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.

Vanda Pharmaceuticals NASDAQ:VNDA

$5.14 +0.06 (+1.08%)

As of 02:12 PM Eastern

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ICCC, PALI, IKT, and VNDA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ICCC, PALI, IKT, and VNDA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ICCC, PALI, IKT, and VNDA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ICCC, PALI, IKT, and VNDA Company Descriptions

ImmuCell NASDAQ:ICCC

Inhibikase Therapeutics NASDAQ:IKT

Palisade Bio NASDAQ:PALI

Vanda Pharmaceuticals NASDAQ:VNDA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ICCC, PALI, IKT, and VNDA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ICCC, PALI, IKT, and VNDA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ICCC, PALI, IKT, and VNDA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ICCC, PALI, IKT, and VNDA Company Descriptions

ImmuCell NASDAQ:ICCC

Inhibikase Therapeutics NASDAQ:IKT

Palisade Bio NASDAQ:PALI

Vanda Pharmaceuticals NASDAQ:VNDA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools